

ENZO BIOCHEM INC
Form SC 13G
February 14, 2019

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Enzo Biochem Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

294100102

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ X

Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 294100102

1 NAME OF REPORTING PERSON

Manulife Financial Corporation

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
N/A (b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Canada

5 SOLE VOTING POWER

-0-

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With

6 SHARED VOTING POWER

-0-

7 SOLE DISPOSITIVE POWER

-0-

8 SHARED DISPOSITIVE POWER

-0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

None, except through its indirect, wholly-owned subsidiaries, Manulife Asset Management (US) LLC and Manulife Asset Management Limited.

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

N/A

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

See line 9 above.

12 TYPE OF REPORTING PERSON*

HC

***SEE INSTRUCTIONS**

Page 2 of 9

CUSIP No. 294100102**1** NAME OF REPORTING PERSON

Manulife Asset Management (US) LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
 N/A (b)

3 SEC USE ONLY**4** CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5SOLE VOTING
POWER

2,932,841

6SHARED VOTING
POWER

-0-

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With

7SOLE DISPOSITIVE
POWER

2,932,841

8SHARED
DISPOSITIVE POWER

-0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON

2,932,841

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES*

N/A

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

6.21%

12 TYPE OF REPORTING PERSON*

IA

***SEE INSTRUCTIONS**

Page 3 of 9

CUSIP No. 294100102**1** NAME OF REPORTING PERSON

Manulife Asset Management Limited

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
 N/A (b)

3 SEC USE ONLY**4** CITIZENSHIP OR PLACE OF ORGANIZATION

Canada

5 SOLE VOTING POWER

10,183

Number of
 Shares
 Beneficially
 Owned by
 Each
 Reporting
 Person
 With

6 SHARED VOTING POWER

-0-

7 SOLE DISPOSITIVE POWER

10,183

8 SHARED DISPOSITIVE POWER

-0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

10,183

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

N/A

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

0.02%

12 TYPE OF REPORTING PERSON*

FI

***SEE INSTRUCTIONS**

Page 4 of 9

CUSIP No. 294100102**1** NAME OF REPORTING PERSON

John Hancock Small Cap Core Fund

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
 N/A (b)

3 SEC USE ONLY**4** CITIZENSHIP OR PLACE OF ORGANIZATION

Massachusetts

5SOLE VOTING
POWER

-0-

6Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
WithSHARED VOTING
POWER

-0-

7SOLE DISPOSITIVE
POWER

-0-

8SHARED
DISPOSITIVE POWER

-0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON

2,733,705 Shares owned directly by the Fund. Manulife Asset Management (US) LLC has sole voting and dispositive power over these shares.

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES*

N/A

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

5.79%

12 TYPE OF REPORTING PERSON*

IV

***SEE INSTRUCTIONS**

Page 5 of 9

Edgar Filing: ENZO BIOCHEM INC - Form SC 13G

- Item 1(a) Name of Issuer:
Enzo Biochem Inc.
- Item 1(b) Address of Issuer's Principal Executive Offices:
527 Madison Ave.
New York, NY 10022
- Item 2(a) Name of Person Filing:
This filing is made on behalf of Manulife Financial Corporation ("MFC") and MFC's indirect, wholly-owned subsidiaries, Manulife Asset Management (US) LLC ("MAM (US)"), Manulife Asset Management Limited ("MAML"), and also made on behalf of the John Hancock Small Cap Core Fund.
- Item 2(b) Address of Principal Business Office:
The principal business offices of MFC and MAML are located at 200 Bloor Street East, Toronto, Ontario, Canada, M4W 1E5.
The principal business office of MAM (US) is located at 197 Clarendon Street, Boston, Massachusetts 02116.
The principal business office of John Hancock Small Cap Core Fund is located at 200 Berkeley Street, Boston, Massachusetts 02117.
- Item 2(c) Citizenship:
MFC and MAML are organized and exist under the laws of Canada.
MAM (US) is organized and exists under the laws of the State of Delaware.
John Hancock Small Cap Core Fund is organized and exists under the laws of the Commonwealth of Massachusetts.
- Item 2(d) Title of Class of Securities:
Common Stock
- Item 2(e) CUSIP Number:
294100102
- Item 3 If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

MFC:	(g) (X)	a parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
MAM (US):	(e) (X)	an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
MAML:	(j) (X)	a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
John Hancock Small Cap Core Fund:	(d) (X)	an investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

Item 4 Ownership:

(a) Amount Beneficially Owned: MAM (US) has beneficial ownership of 2,943,024 shares of Common Stock, of which John Hancock Small Cap Core Fund owns directly 2,733,705 shares and MAML has beneficial ownership of 10,183 shares of Common Stock. Through its parent-subsidiary relationship to MAM (US) and MAML, MFC may be deemed to have beneficial ownership of these same shares.

Edgar Filing: ENZO BIOCHEM INC - Form SC 13G

(b) Percent of Class: Of the 47,192,429 shares of common stock outstanding as of December 1, 2018, according to the Form 10-K filed by the issuer with the Securities and Exchange Commission on December 10, 2018, MAM (US) held 6.21%, of which John Hancock Small Cap Core Fund held directly 5.79% and MAML held 0.02%.

(c) Number of shares as to which the person has:

- (i) sole power to vote or to direct the vote:
MAM (US) and MAML each has sole power to vote or to direct the voting of the shares of Common Stock beneficially owned by each of them.
- (ii) shared power to vote or to direct the vote: -0-

sole power to dispose or to direct the disposition of:
MAM (US) and MAML each has sole power to dispose or to direct the disposition of the shares of Common Stock beneficially owned by each of them.
- (iii) shared power to dispose or to direct the disposition of: -0-

Item 5 Ownership of Five Percent or Less of a Class:
Not applicable.

Item 6 Ownership of More than Five Percent on Behalf of Another Person:
Not applicable.

Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
See Items 3 and 4 above.

Item 8 Identification and Classification of Members of the Group:
Not applicable.

Item 9 Notice of Dissolution of Group:
Not applicable.

Item 10 Certification:
By signing below the undersigned certifies that, to the best of its knowledge and belief, (i) the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, and (ii) the foreign regulatory scheme applicable to MAML, is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. The undersigned also undertakes to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Manulife Financial Corporation

By: /s/ Susie Rafael

Name: Susie Rafael

Dated: February 6, 2019 Title: Agent*

Manulife Asset Management (US) LLC

By: /s/ Paul Donahue

Name: Paul Donahue

Dated: February 5, 2019 Title: Chief Compliance Officer

Manulife Asset Management Limited

By: /s/ Christopher Walker

Name: Christopher Walker

Dated: February 5, 2019 Title: Chief Compliance Officer

John Hancock Small Cap Core Fund

By: /s/ Frank Knox

Name: Frank Knox

Dated: February 11, 2019 Title: Chief Compliance Officer, U.S Investment Management

* Signed pursuant to a Power of Attorney dated January 17, 2018 included as Exhibit A to Schedule 13F-NT filed with the Securities and Exchange Commission by Manulife Financial Corporation on January 29, 2018.

EXHIBIT A

JOINT FILING AGREEMENT

Manulife Financial Corporation, Manulife Asset Management (US) LLC and Manulife Asset Management Limited agree that the Schedule 13G to which this Agreement is attached, relating to the Common Stock of Eco Biochem Inc., is filed on behalf of each of them.

Manulife Financial Corporation

By: /s/ Susie Rafael

Name: Susie Rafael

Dated: February 6, 2019 Title: Agent*

Manulife Asset Management (US) LLC

By: /s/ Paul Donahue

Name: Paul Donahue

Dated: February 5, 2019 Title: Chief Compliance Officer

Manulife Asset Management Limited

By: /s/ Christopher Walker

Name: Christopher Walker

Dated: February 5, 2019 Title: Chief Compliance Officer

John Hancock Small Cap Core Fund

By: /s/ Frank Knox

Name: Frank Knox

Dated: February 11, 2019 Title: Chief Compliance Officer, U.S Investment Management

* Signed pursuant to a Power of Attorney dated January 17, 2018 included as Exhibit A to Schedule 13F-NT filed with the Securities and Exchange Commission by Manulife Financial Corporation on January 29, 2018.